IHH Healthcare has announced impressive financial results for the second quarter of 2024, showcasing significant double-digit growth across key metrics. The group's revenue surged by 30% to RM6.1 billion, while EBITDA rose 34% to RM1.4 billion. Profit After Tax and Minority Interests (PATMI), excluding exceptional items, increased by 39% to RM437 million. PATMI, including all items, more than doubled to RM623 million.
For the first half of 2024, IHH Healthcare continued its strong performance with a 23% rise in revenue to RM12.0 billion and a 26% increase in EBITDA to RM2.7 billion. PATMI, excluding exceptional items, grew by 30% to RM840 million. However, PATMI, including all items, fell by 18% due to a high base last year, which benefited from RM862 million in one-off gains from the sale of International Medical University (IMU).
Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare, commented, "We have delivered an outstanding performance in the first half of 2024, marked by two consecutive quarters of record revenue and strong operational excellence. Our focus on providing quality patient care and excellent outcomes remains paramount. Our recent initiatives, including the launch of IHH Singapore's first transitional care facility and Fortis Memorial Research Institute's new Gamma Knife Esprit treatment, further solidify our position as a leader in healthcare."
The group's operational summary for Q2 2024 highlights sustained growth, with revenue and EBITDA reflecting strong patient volume and complex case management across all markets. PATMI more than doubled, driven by strong operational performance, deferred tax credits, and net monetary gains from applying MFRS 129. Excluding exceptional items, PATMI (ex EI) saw a 39% increase.
IHH Healthcare has recently made strategic appointments to its Board of Directors, including Tan Sri Dr Nik Norzrul Thani Nik Hassan Thani as Chairman and Independent Non-Executive Director, and Chua Bin Hwee as Audit Committee Chairman and Independent Non-Executive Director. Additionally, the group has expanded its facilities and capabilities, such as breaking ground on TCF@East, IHH Singapore's first transitional care facility, and introducing Gamma Knife Esprit at Fortis Memorial Research Institute.
IHH醫療集團宣佈了2024年第二季度的驕人業績，在各項關鍵指標上都取得了兩位數的顯著增長。該集團的收入激增 30%，達到 61 億令吉，息稅折舊攤銷前利潤（EBITDA）增長 34%，達到 14 億令吉。不包括特殊項目的稅後和少數股東權益（PATMI）增長了39%，達到4.37億令吉。包括所有項目在內的稅後及少數股東權益（PATMI）增長了一倍多，達到 6.23 億令吉。
2024 年上半年，IHH 醫療保健繼續保持強勁表現，營收增長 23% 至 120 億令吉，息稅折舊攤銷前利潤（EBITDA）增長 26% 至 27 億令吉。不包括特殊項目的PATMI增長了30%，達到8.4億令吉。然而，包括所有項目在內的PATMI則下跌18%，原因是去年的基數較高，受惠於出售國際醫科大學（IMU）的8億6千2百萬令吉一次性收益。
IHH醫療集團首席執行官Prem Kumar Nair博士評論道："我們在2024年上半年取得了出色的業績表現，連續兩個季度創下創紀錄的收入和卓越的運營表現。我們始終專注於提供優質的患者護理和卓越的療效。我們最近推出的舉措，包括 IHH 新加坡首家過渡性護理設施的啓動和富通紀念研究所的新型伽瑪刀 Esprit 治療，進一步鞏固了我們在醫療保健領域的領先地位。
集團 2024 年第二季度的運營總結顯示了持續的增長，收入和息稅折舊攤銷前利潤（EBITDA）反映了所有市場強勁的患者數量和複雜的病例管理。在強勁的運營業績、遞延稅款抵免和應用 MFRS 129 帶來的淨貨幣收益的推動下，PATMI 增長了一倍多。剔除特殊項目後，PATMI（不包括 EI）增長了 39%。
IHH Healthcare 最近對董事會進行了戰略性任命，包括任命 Tan Sri Dr Nik Norzrul Thani Nik Hassan Thani 爲主席兼獨立非執行董事，任命 Chua Bin Hwee 爲審計委員會主席兼獨立非執行董事。此外，集團還擴大了其設施和能力，如 IHH 新加坡首個過渡性護理設施 TCF@East 破土動工，並在富通紀念研究所引進了伽瑪刀 Esprit。
